Company Attovia Therapeutics, Inc.

Stocks

ATTO

US04987L1026

Biotechnology & Medical Research

Market Closed - Nasdaq 20:00:00 30/10/2026 GMT			5-day change	1st Jan Change
15.19 ^USD	-0.52%		+9.83%	-

09-20	Attovia Therapeutics, Inc.(NasdaqGM:ATTO) added to S&P TMI Index	CI
09-16	Attovia Therapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 10:00 AM

Business description: Attovia Therapeutics, Inc.

Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases with high unmet need. Its lead pipeline candidates target commercially validated pathways and are designed through its ATTOBODY biologics platform to deliver improved treatments relative to the standards of care. Its ATTOBODY platform uses an evolution-driven, high-throughput process which allows for discovery and creation of a high diversity of potential product candidates. It is developing a pipeline of novel biotherapeutics for the treatment of immune-mediated diseases. Its first two product candidates for its immune-dermatology franchise, ATTO-1310 and ATTO-2306, have the potential to treat patients suffering from pruritic and lesional diseases. Its third program, ATTO-1091, broadens its reach to other inflammatory diseases, such as IBD, a therapeutic area with substantial unmet need. ATTO-1310 is an ATTOBODY-based therapeutic targeting interleukin-31.

Number of employees: 44

Sales by Activity: Attovia Therapeutics, Inc.

Fiscal Period: December	2024 (USD)	2025 (USD)
Development of Therapeutic Products in The Fields of Immune-Mediated Diseases	-	1.35M

See all business segments

Geographical breakdown of sales: Attovia Therapeutics, Inc.

Fiscal Period: December	2024 (USD)	2025 (USD)
United States of America	-	1.35M

See all geographic segments

Executive Committee: Attovia Therapeutics, Inc.

Manager	Title	Age	Since
Hangjun Zhan CTO	Chief Tech/Sci/R&D Officer	-	15/12/2022
Petter Veiby CTO	Chief Tech/Sci/R&D Officer	61	31/05/2023
Tao Fu CEO	Chief Executive Officer	54	31/03/2023
Zaneta Odrowaz SEC	Corporate Secretary	42	31/03/2023
Steven Chan DFI	Director of Finance/CFO	54	30/09/2024

See ATTOVIA THERAPEUTICS, INC. governance

Composition of the Board of Directors: Attovia Therapeutics, Inc.

Director	Title	Age	Since
Aaron Royston BRD	Director/Board Member	42	31/05/2023
Tao Fu BRD	Director/Board Member	54	31/03/2023
James Topper CHM	Chairman	64	31/05/2023
Angie You BRD	Director/Board Member	53	30/06/2024
Mitchell Gold BRD	Director/Board Member	59	30/06/2024
John Smither BRD	Director/Board Member	73	30/06/2026
Colin Walsh BRD	Director/Board Member	40	30/04/2024

Composition of the Board of Directors

Shareholders: Attovia Therapeutics, Inc.

Name	Stocks	%	Valuation
Frazier Life Sciences Management LP 15.27 %	6,968,703	15.27 %	119 M $
venBio Partners LLC 9.159 %	4,181,367	9.159 %	72 M $
Alamar Holdco LLC 7.074 %	3,229,279	7.074 %	55 M $
Goldman Sachs & Co. LLC (Private Banking) 6.617 %	3,020,632	6.617 %	52 M $
Redmile Group LLC 4.744 %	2,165,708	4.744 %	37 M $

List of ATTOVIA THERAPEUTICS, INC. shareholders

Company details: Attovia Therapeutics, Inc.

Attovia Therapeutics

1091 Industrial Road

94070, San Carlos

http://www.attovia.com

address Attovia Therapeutics, Inc.(ATTO)

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ATTOVIA THERAPEUTICS, INC.	-0.52%	+9.83%	-	-	693M
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+42.87%	+64.15%	63.77B
ARGENX SE	+0.35%	+3.20%	+14.40%	+81.76%	56.37B
LONZA GROUP AG	+0.53%	+1.96%	+16.24%	+103.35%	54.62B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+47.83%	44.06B
BEONE MEDICINES AG	-0.33%	-1.93%	+19.28%	+98.80%	42.11B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+225.14%	+866.21%	41B
GENMAB A/S	+3.27%	+47.96%	+112.84%	+96.58%	34.92B
CELLTRION, INC.	+1.22%	-1.44%	+14.57%	+46.95%	32.82B
INSMED INCORPORATED	+0.89%	+20.55%	-40.62%	+349.24%	24.7B
Average	+0.25%	+7.77%	+47.58%	+194.99%	39.5B
Weighted average by Cap.	+0.18%	+5.45%	+47.99%	+176.67%